Review of Contemporary Philosophy
ISSN: 1841-5261, e-ISSN: 2471-089X
Vol 23 (2), 2024
pp. 6888 - 6895

Prostate Imaging: Notes for Radiologists, Nurses, and Public Health Workers

[1] Ahmed Mosa Humadi, [2] Hamoud Mohammed Shibli

[1]Radiological Technology Jazan university College of dentistry

[2]Radiological Technology Jazan university College of dentistry

Abstract:

Background: The prostate gland, a vital component of the male reproductive system, is prone to various pathologies, including benign prostatic hyperplasia (BPH), prostatitis, and prostate carcinoma. Imaging plays a crucial role in diagnosing, staging, and managing these conditions, with modalities such as computed tomography (CT), magnetic resonance imaging (MRI), ultrasonography (US), and nuclear medicine offering unique advantages. Beyond imaging, nursing and public health play pivotal roles in patient education, early detection, and management of prostate-related conditions.

Aim: This article aims to provide a comprehensive overview of imaging techniques used in prostate evaluation, highlighting their roles in diagnosing and managing prostate-related conditions. Additionally, it emphasizes the contributions of nursing and public health in prostate care.

Methods: The review discusses the anatomical and histological features of the prostate, followed by an in-depth analysis of imaging modalities, including CT, MRI, US, and nuclear medicine. Each modality's strengths, limitations, and specific applications in diagnosing BPH, prostatitis, and prostate carcinoma are explored. Advanced techniques such as multiparametric MRI (mp-MRI), elastography, and contrast-enhanced ultrasound (CEUS) are also discussed. The roles of nursing in patient care and public health in awareness and prevention are integrated into the discussion.

Results: CT is useful for staging prostate cancer and assessing metastases but has limited resolution for detailed prostate anatomy. MRI, particularly mp-MRI, excels in detecting malignancies, guiding biopsies, and differentiating prostate zones. Ultrasonography, especially transrectal ultrasound (TRUS), is widely used for prostate volume assessment and biopsy guidance, with advancements like elastography and CEUS improving diagnostic accuracy. Nuclear medicine, including PET/CT and PSMA-based imaging, is invaluable for detecting metastases and guiding therapy. Nursing plays a critical role in patient education, symptom management, and post-procedure care, while public health initiatives focus on early detection, screening programs, and reducing health disparities.

Conclusion: Imaging is indispensable in the diagnosis and management of prostate pathologies. MRI and US are particularly effective for localized disease, while nuclear medicine and CT are essential for staging and metastatic evaluation. Advances in imaging technology continue to enhance diagnostic precision and therapeutic outcomes. Nursing and public health are integral to holistic prostate care, ensuring patient-centered approaches and population-level interventions to improve outcomes.

Keywords: Prostate imaging, MRI, CT, ultrasonography, nuclear medicine, BPH, prostate carcinoma, prostatitis, nursing, public health.

Received: 07 November 2024 **Revised:** 19 December 2024 **Accepted**: 26 December 2024

Introduction:

The prostate is a gland resembling the shape of a walnut and is a crucial component of the male reproductive system. Its primary function is to produce and secrete a thin, alkaline fluid that forms part of the ejaculate. This gland consists of both glandular and stromal tissues, which are prone to enlargement and the development of adenocarcinoma, particularly in older males. In contrast, infections such as prostatitis are more commonly observed in younger individuals. Imaging techniques play a pivotal role in diagnosing various prostatic pathologies, including the early detection of carcinoma. Additionally, imaging is instrumental in guiding tissue sampling, draining abscesses, managing post-procedural collections, and staging and monitoring malignant conditions. Anatomically, the prostate is situated in the pelvic cavity, positioned inferior to the urinary bladder and encircling the prostatic urethra. Structurally, it comprises an apex that rests on the urogenital diaphragm, a base connected to the bladder neck, and inferolateral surfaces that lie on the levator ani fascia above the urogenital diaphragm. For a detailed visual representation, refer to the image titled *Median Sagittal Section of Male Pelvis Anatomy*. The prostate is anatomically divided into two lateral lobes (right and left) and one median lobe. Histologically, it is organized into three distinct zones: the central zone (CZ), which constitutes approximately 25% of the prostatic mass and forms the base; the peripheral zone (PZ), which surrounds the central zone and also makes up about 25% of the gland's mass; and the transition zone (TZ), which envelops the anterolateral portion of the urethra in a horseshoe-like configuration. Understanding these histological zones is critical, as 70% of adenocarcinomas originate in the peripheral zone, while 20% arise in the transition zone. Only 10% of adenocarcinomas develop in the central zone. In contrast, prostatitis predominantly affects the central zone, whereas benign prostatic hyperplasia (BPH) typically involves the expansion of the transition zone, leading to the formation of adenomas.

Computed Tomography (CT):

Plain radiographs have limited utility in evaluating the prostate but are occasionally employed as part of a skeletal survey to detect or monitor metastatic disease. For assessing bone metastases, other imaging modalities such as bone scans are more commonly utilized. Additionally, computed tomography (CT) of the chest, abdomen, and pelvis is frequently used for staging prostate cancer. Magnetic resonance imaging (MRI) of the prostate is particularly valuable due to its high sensitivity and specificity in evaluating prostate malignancy and local tumor extension. Both CT and MRI are also instrumental in guiding the placement of radiation seeds during radiotherapy. When it comes to computed tomography (CT), the detailed anatomy of the prostate is not clearly visualized, nor are its pathological changes distinctly defined. On CT scans, the central zone may appear hyperdense, with a density ranging between 40 to 60 Hounsfield Units (HU), while the peripheral zone typically appears hypodense, with densities between 10 to 5 HU. Although CT is not the primary modality for diagnosing benign prostatic hyperplasia (BPH), it can identify BPH when the prostate gland extends above the pubic symphysis on axial imaging. BPH can also be diagnosed on CT when the prostate volume exceeds 30 mL, as measured using coronal reformatted images. In cases of prostatitis, the prostate gland may appear diffusely hypodense on CT scans, with either symmetric or asymmetric enlargement. Prostatic abscesses, on the other hand, are characterized by well-defined hypoattenuating areas, typically with fluid densities ranging from -19 to 13 HU, and often exhibit peripheral rim enhancement. CT scans can be used to monitor disease progression, although sonography is sometimes preferred as an alternative imaging method. Prostate carcinoma (CA) on CT scans often presents as contrast-enhancing areas, particularly during the venous phase. These enhancements can be either focal or diffuse and are predominantly located within the peripheral zone. While CT is not the primary tool for diagnosing prostate cancer, it plays a significant role in imaging by assessing both local and distant spread of the disease, aiding in staging and treatment planning [1][2].

Magnetic Resonance Imaging (MRI):

Magnetic Resonance Imaging (MRI) has emerged as a superior modality for prostate imaging due to its exceptional contrast resolution, which allows for the differentiation of anatomical zones and the identification of abnormalities within these regions. Prostate MRI is typically performed using a pelvic coil, which is highly sensitive in detecting malignancies and assessing their local extension. The use of an endorectal coil further enhances image resolution and provides more detailed information (see Image. Normal Prostate, Magnetic Resonance Image Using Endorectal Coil). Recent advancements, such as multiparametric MRI (mp-MRI), functional MRI, and MRI-guided biopsies, have significantly improved the detection of low-grade or low-volume prostate carcinomas. Essential MRI sequences for prostate imaging include T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping, and dynamic contrast-enhanced imaging. DWI evaluates the diffusion of water molecules at the cellular level, while ADC provides a qualitative measure of average water diffusion per voxel. These techniques are particularly valuable in diagnosing prostate carcinoma and prostatitis, including abscesses [3].

Normal Anatomy on MRI

On T2-weighted imaging (T2WI), the peripheral zone of the prostate appears homogeneously hyperintense, with a distinct hypointense capsule. In contrast, the transition zone exhibits heterogeneity, and the seminal vesicles appear uniformly hyperintense on T2WI. These distinct signal characteristics allow for clear visualization of the prostate's zonal anatomy, which is critical for identifying pathological changes.

Benign Prostatic Hyperplasia (BPH) on MRI

MRI is highly effective in delineating the zonal anatomy of the prostate, including gland volume and zonal volume. In cases of benign prostatic hyperplasia (BPH), the transition zone appears heterogeneous on T2WI. The enlargement of glandular or stromal tissues in BPH results in nodules that may exhibit either increased or decreased signals on T2WI. Specifically, glandular enlargement appears as bright signals on T2WI, while fibromuscular and stromal elements appear dark. The ratio of stromal to glandular tissue is an important factor in determining the appropriate medical therapy for BPH [4]. Stromal hyperplasia, which can mimic transitional zone cancer due to its low intensity on T2WI, diffusion restriction, and contrast enhancement, can be differentiated by its well-defined and encapsulated appearance [5]. BPH can be classified into seven types based on MRI findings: Type 0 (no or minimal zonal enlargement), Type 2 (retrourethral), Type 3 (retrourethral + bilateral transition zone), Type 4 (pedunculated, either multiple or solitary), Type 5 (pedunculated + bilateral transition zone +/- retrourethral), Type 6 (subtrigonal or ectopic enlargement), and Type 7 (other combinations). MRI not only aids in diagnosing BPH but also plays a crucial role in identifying carcinoma in patients with BPH who have elevated prostate-specific antigen (PSA) levels and are at high risk for prostate cancer [4].

Prostate Infection on MRI

Prostatitis, which can be acute or chronic, is more commonly observed in the peripheral zone. Acute prostatitis appears hyperintense on T2WI with increased contrast enhancement, while chronic prostatitis typically appears hypointense on T2WI and shows poor contrast enhancement. Chronic prostatitis often exhibits diffuse diffusion restriction due to inflammatory cell infiltration, which can mimic prostate carcinoma. However, the degree of diffusion restriction is generally lower in prostatitis compared to carcinoma. Non-necrotic granulomatous prostatitis also appears hypointense on T2WI with diffusion restriction but lacks enhancement on post-contrast imaging. In contrast, necrotic areas of granulomatous prostatitis show increased signal intensity on T2WI. Differentiating granulomatous prostatitis with extra-prostatic extension from carcinoma can be challenging [5][6]. Prostatic abscesses, a complication of prostatitis, hyperintense appear on T2WI, hypointense on T1-weighted imaging (T1WI), and exhibit peripheral contrast enhancement. These abscesses also show diffusion restriction and low ADC values [7].

Prostate Malignancy on MRI

Prostate carcinoma is a leading cause of morbidity and mortality worldwide. MRI, particularly mp-MRI, has become an invaluable tool for cancer detection, helping to avoid unnecessary biopsies. Pre-biopsy MRI and MRI-guided biopsies are superior to transrectal ultrasound (TRUS)-guided biopsies in terms of accuracy [8]. Pre-biopsy MRI also helps mitigate over-staging errors that may arise due to biopsy artifacts [9]. MRI is particularly effective in detecting tumors in the anterior, lateral, and apical regions of the prostate, which are often missed by TRUS-guided biopsies. Malignant lesions are typically located in the peripheral zone and appear as hypointense on T2WI, with focal enhancement and low diffusivity. Ill-defined, hypointense lesions in the peripheral zone are highly suspicious for carcinoma. Although less common, malignancies in the transition zone may appear as non-circumscribed, spiculated, and relatively hypointense lesions on

T2WI. MRI is also instrumental in assessing metastases that are not visible on bone scans or CT. It is particularly useful for evaluating pathological fractures and associated complications. The Prostate Imaging Reporting and Data System (PI-RADS) is a standardized classification system based on mp-MRI findings, with the latest update in 2015 known as PI-RADS version 2 (PI-RADS™ v2). This system categorizes the likelihood of clinically significant carcinoma as follows:

- **PI-RADS 1**: Highly unlikely; normal T2WI and DWI/ADC.
- **PI-RADS 2**: Unlikely; circumscribed heterogeneity on T2WI and hypointensity in the peripheral zone on DWI/ADC (see Image. Magnetic Resonance Image of Prostate, Imaging Reporting and Data System-2 Classification).
- **PI-RADS 3**: Equivocal; heterogeneous lesion with obscured margins on T2WI, hyperintense on DWI, and hypointense on ADC (see Image. Magnetic Resonance Image of Prostate, Imaging Reporting and Data System 3 Classification).
- **PI-RADS 4**: Likely; non-circumscribed lesion ≤ 1.5 cm, moderately homogeneously hypointense on T2WI, hyperintense on DWI, and hypointense on ADC.
- **PI-RADS 5**: Highly likely; similar to PI-RADS 4 but with a lesion > 1.5 cm or evidence of extra-prostatic extension.

In conclusion, MRI, particularly mp-MRI, has revolutionized the diagnosis and management of prostate pathologies, including BPH, prostatitis, and prostate carcinoma. Its ability to provide detailed anatomical and functional information makes it an indispensable tool in modern urology.

Ultrasonography (US):

Ultrasonography (US) is a widely accessible and versatile imaging modality for evaluating the prostate, as well as for performing guided prostate biopsies. Both transabdominal ultrasound (TAUS) and transrectal ultrasound (TRUS) can be utilized for prostate assessment, with TRUS being the preferred method for biopsy procedures due to its superior resolution and detailed visualization of the gland (see Image. Transrectal Ultrasound Guided Biopsy of the Prostate). During TAUS, the transducer is placed just above the pubic symphysis, and a fluid-filled urinary bladder serves as an acoustic window to visualize the prostate. The average normal prostate measurements are approximately 3.75 to 4.00 cm in width, 2.5 to 3.00 cm in height, and 3.1 to 3.8 cm in length, with a volume ranging between 20 to 25 cm^3. The prostate volume is calculated using the ellipsoid formula: 0.5236 × height (H) × width (W) × length (L) [10]. However, TAUS has limitations, particularly in obese patients or when adequate bladder filling cannot be achieved, which may hinder accurate prostate volume assessment. In such cases, TRUS is the preferred alternative. TRUS is also indicated for evaluating suspected prostatic pathologies identified during clinical examinations, elevated prostate-specific antigen (PSA) levels, prostatic inflammation or abscesses, and for monitoring prostate cancer. TRUS provides a more detailed evaluation of the prostate gland and surrounding structures compared to TAUS [11]. For TRUS, an endorectal transducer with a frequency of 8 to 10 MHz is gently inserted into the rectum. Prostate volume is measured similarly to TAUS by obtaining width, height, and length measurements. The gland is assessed for its shape, symmetry, echogenicity, and the integrity of the prostatic capsule. Additionally, periprostatic structures such as seminal vesicles, neurovascular bundles, and blood vessels are evaluated for abnormalities, particularly in cases of suspected prostate carcinoma. Elastography, a supplementary technique performed during TRUS, assesses the firmness of prostate tissue. Areas of increased firmness, which may not exhibit abnormal echogenicity on grayscale imaging, can be identified using elastography, aiding in the detection of suspicious lesions [11].

Benign Prostatic Hyperplasia (BPH) on Ultrasonography

Both TAUS and TRUS are used to assess prostate volume, which is critical for determining the appropriate management strategy for benign prostatic hyperplasia (BPH). A prostate volume exceeding 80 cm^3 typically qualifies for open surgical adenomectomy, while smaller volumes may be managed with transurethral resection of the prostate (TURP). The European Association of Urology (EAU) recommends measuring prostate volume via TRUS and assessing post-void residual urine volume using TAUS. Additionally, ultrasound examination should include visualization of the upper urinary tract to evaluate the degree of urinary tract dilatation, which may occur secondary to BPH [10].

Prostate Inflammation on Ultrasonography

Prostatitis is primarily a clinical diagnosis, but ultrasonography can provide valuable imaging findings. In cases of prostatitis, the prostate gland often appears enlarged and/or deformed with an inhomogeneous echotexture on ultrasound. Acute prostatitis may lead to the formation of parenchymal abscesses, which appear as hypoechoic or fluid-filled lesions within the prostate parenchyma. Ultrasound is not only diagnostic but also therapeutic, as it can guide the evacuation of abscesses. In chronic prostatitis, ultrasound may be used to guide intraprostatic antibiotic injections, particularly when pain exacerbations occur [12].

Prostatic Neoplasms on Ultrasonography

Diagnosing prostate malignancy using ultrasound can be challenging, as tumors are often isoechoic to the surrounding normal prostate tissue. However, some malignancies may appear hypoechoic. Color Doppler or power Doppler ultrasound can identify angiogenesis, characterized by dilated and tortuous vessels, but these techniques are limited in detecting small tumor foci. The diagnostic accuracy of ultrasound for prostate cancer is approximately 30% to 40%, making it primarily useful as a guidance tool for prostate biopsies rather than a standalone diagnostic modality [11]. Ultrasound-guided biopsies have been shown to improve cancer detection rates, particularly in men with elevated PSA levels or abnormal PSA ratios [13]. Ultrasound is also valuable for identifying local tumor spread, aiding in cancer staging. Advanced techniques such as elastography, which assesses tissue consistency, can help differentiate malignant lesions from normal tissue. Malignant areas typically appear firmer than surrounding normal tissue on elastography. Three-dimensional TRUS (3D-TRUS) allows for computer processing of sectional images, providing more detailed information about prostate morphology and surrounding structures. Contrast-enhanced ultrasound (CEUS) has shown high sensitivity in differentiating neoplastic tissue from normal prostate tissue, further enhancing the accuracy of ultrasound-guided biopsies [14].

Advances in Ultrasonography for Prostate Evaluation

Recent advancements in ultrasound technology have significantly improved its diagnostic capabilities for prostate evaluation. Elastography, for instance, provides additional information about tissue stiffness, which can help identify suspicious areas that may not be apparent on conventional grayscale imaging. Three-dimensional TRUS offers enhanced visualization of the prostate and surrounding structures, improving the accuracy of volume measurements and morphological assessments. Contrast-enhanced ultrasound (CEUS) utilizes microbubble contrast agents to highlight vascular patterns within the prostate, improving the detection of neoplastic lesions and guiding targeted biopsies [14]. In conclusion, ultrasonography is a versatile and widely available imaging modality for prostate evaluation, offering both diagnostic and therapeutic applications. While it has limitations in directly diagnosing prostate cancer, its role in guiding biopsies, assessing prostate volume, and evaluating prostatic inflammation and abscesses is invaluable. Advances such as elastography, 3D-TRUS, and CEUS have further enhanced its utility, making it an essential tool in the management of prostate-related conditions.

Nuclear Imaging and Angiography:

Nuclear medicine plays a significant role in the diagnosis, staging, re-staging, and therapy of prostate carcinoma. One of its primary applications is the identification of skeletal metastases through bone scans, which are highly sensitive in detecting osseous involvement. Positron emission tomography (PET) is another critical tool in nuclear medicine, used to assess malignant activity and its spread throughout the body. Specifically, the choline derivative radiotracer, 18F-fluorocholine (F-FCH), is commonly employed for diagnosing prostate carcinoma. When PET is combined with computed tomography (CT) or magnetic resonance imaging (MRI), it provides both metabolic/functional data from PET and anatomical details from CT or MRI, enhancing diagnostic accuracy and staging precision [15][16]. Another advanced tracer in nuclear medicine is the gallium (Ga)-labeled prostate-specific membrane antigen (PSMA) inhibitor. PSMA is highly expressed on the surface of prostate carcinoma cells, nodal metastases, and bone metastases. This tracer is increasingly used not only for diagnostic purposes but also for therapeutic applications, such as targeted radioligand therapy, making it a versatile tool in the management of prostate cancer [16]. In addition to nuclear medicine, angiography is utilized in urology for prostatic artery embolization (PAE), particularly in patients with benign prostatic hyperplasia (BPH) and associated bleeding. PAE is an interventional technique that improves lower urinary tract symptoms (LUTS) secondary to BPH by reducing prostate volume and vascularity. This minimally invasive procedure has shown promising results in alleviating symptoms and improving quality of life for patients with BPH [17].

Role of Nursing and Public Health in Prostate Care

Nurses play a pivotal role in the comprehensive management of prostate-related conditions, contributing significantly to patient education, symptom management, and emotional support. They are often the first point of contact for patients, providing essential information about prostate health, risk factors, and the importance of early detection through regular screenings such as prostate-specific antigen (PSA) tests and digital rectal exams (DRE). Nurses also guide patients on lifestyle modifications, including dietary changes and physical activity, which may help reduce the risk of prostate conditions. During diagnostic procedures, such as imaging studies (e.g., MRI, TRUS) and biopsies, nurses prepare patients by explaining the processes, addressing concerns, and ensuring informed consent. Post-procedure, they monitor complications, such as bleeding or infection, and provide follow-up care. Additionally, nurses assist in managing symptoms associated with prostate conditions, such as urinary retention, incontinence, and pain, particularly in patients with benign prostatic hyperplasia (BPH) or prostate cancer. They also play a crucial role in administering medications, such as alpha-blockers or 5-alpha reductase inhibitors, and monitoring for side effects. Beyond physical care, nurses offer emotional support, helping patients and their families cope with the psychological burden of a prostate cancer diagnosis or chronic prostate conditions.

Public health initiatives are equally vital in addressing prostate health at the population level. Public health professionals focus on raising awareness about prostate conditions, promoting early detection, and reducing health disparities. They design and implement screening programs to ensure that high-risk populations, such as older men and those with a family history of prostate cancer, have access to timely and affordable diagnostic services. Public health campaigns also aim to educate communities about the importance of regular check-ups and the availability of advanced imaging techniques, such as multiparametric MRI and PSMA-based imaging, for accurate diagnosis and staging. Additionally, public health efforts address disparities in prostate care by targeting underserved populations, including racial and ethnic minorities, who often face barriers to accessing quality healthcare. By collaborating with healthcare providers, policymakers, and community organizations, public health professionals work to improve prostate health outcomes through preventive measures, early intervention, and equitable access to care. Together, nursing and public health form a synergistic partnership that enhances both individual patient care and population-level health outcomes in the context of prostate-related conditions.

Conclusion:

Imaging techniques have revolutionized the diagnosis and management of prostate-related conditions, offering detailed insights into the gland's anatomy and pathology. Computed tomography (CT) remains a cornerstone for staging prostate cancer and assessing metastatic spread, particularly in evaluating bone and lymph node involvement. However, its limited resolution for detailed prostate anatomy underscores the need for complementary modalities. Magnetic resonance imaging (MRI), especially multiparametric MRI (mp-MRI), has emerged as the gold standard for localized prostate cancer detection, offering superior contrast resolution and the ability to differentiate between benign and malignant lesions. MRI's role in guiding biopsies and avoiding unnecessary procedures has significantly improved diagnostic accuracy and patient outcomes. Ultrasonography, particularly transrectal ultrasound (TRUS), is a versatile and widely accessible tool for prostate evaluation. It is indispensable for measuring prostate volume, guiding biopsies, and assessing conditions like BPH and prostatitis. Advances such as elastography and contrast-enhanced ultrasound (CEUS) have further enhanced its diagnostic capabilities, enabling the detection of suspicious lesions that may be missed on conventional imaging. Nuclear medicine, including PET/CT and PSMA-based imaging, has transformed the staging and therapeutic management of prostate cancer. These modalities provide functional and metabolic data, allowing for precise localization of metastases and targeted radioligand therapy. Despite these advancements, each imaging modality has its limitations. CT and MRI are resource-intensive and may not be accessible in all settings, while ultrasonography, though widely available, has lower sensitivity for detecting small tumor foci. Nuclear medicine, while highly effective, involves radiation exposure and requires specialized infrastructure. Future developments in imaging technology, such as artificial intelligence integration and novel contrast agents, hold promise for further improving diagnostic accuracy and personalized treatment strategies. In conclusion, a multimodal imaging approach, tailored to the patient's clinical context, is essential for optimal prostate disease management. Collaboration between radiologists, urologists, and oncologists is crucial to leveraging the strengths of each modality and ensuring the best possible outcomes for patients.

References:

1. Thornhill BA, Morehouse HT, Coleman P, Hoffman-Tretin JC. Prostatic abscess: CT and sonographic findings. AJR Am J Roentgenol. 1987 May;148(5):899-900.
2. Jia JB, Houshyar R, Verma S, Uchio E, Lall C. Prostate cancer on computed tomography: A direct comparison with multi-parametric magnetic resonance imaging and tissue pathology. Eur J Radiol. 2016 Jan;85(1):261-267.
3. Stabile A, Giganti F, Emberton M, Moore CM. MRI in prostate cancer diagnosis: do we need to add standard sampling? A review of the last 5 years. Prostate Cancer Prostatic Dis. 2018 Nov;21(4):473-487.
4. Guneyli S, Ward E, Thomas S, Yousuf AN, Trilisky I, Peng Y, Antic T, Oto A. Magnetic resonance imaging of benign prostatic hyperplasia. Diagn Interv Radiol. 2016 May-Jun;22(3):215-9.
5. Kitzing YX, Prando A, Varol C, Karczmar GS, Maclean F, Oto A. Benign Conditions That Mimic Prostate Carcinoma: MR Imaging Features with Histopathologic Correlation. Radiographics. 2016 Jan-Feb;36(1):162-75.
6. Bour L, Schull A, Delongchamps NB, Beuvon F, Muradyan N, Legmann P, Cornud F. Multiparametric MRI features of granulomatous prostatitis and tubercular prostate abscess. Diagn Interv Imaging. 2013 Jan;94(1):84-90.
7. Singh P, Yadav MK, Singh SK, Lal A, Khandelwal N. Case series: Diffusion weighted MRI appearance in prostatic abscess. Indian J Radiol Imaging. 2011 Jan;21(1):46-8.
8. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM., PRECISION Study Group Collaborators. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018 May 10;378(19):1767-1777.
9. van der Leest M, Israël B, Cornel EB, Zámecnik P, Schoots IG, van der Lelij H, Padhani AR, Rovers M, van Oort I, Sedelaar M, Hulsbergen-van de Kaa C, Hannink G, Veltman J, Barentsz J. High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility. Eur Urol. 2019 Nov;76(5):574-581.
10. Guideline developed in collaboration with the American College of Radiology; Society of Radiologists in Ultrasound. AIUM Practice Guideline for the Performance of an Ultrasound Evaluation of the Prostate (and Surrounding Structures). J Ultrasound Med. 2015 Aug;34(8):1-6.
11. Tyloch JF, Wieczorek AP. The standards of an ultrasound examination of the prostate gland. Part 1. J Ultrason. 2016 Dec;16(67):378-390.
12. Tyloch JF, Wieczorek AP. The standards of an ultrasound examination of the prostate gland. Part 2. J Ultrason. 2017 Mar;17(68):43-58

13. Stamatiou K, Alevizos A, Karanasiou V, Mariolis A, Mihas C, Papathanasiou M, Bovis K, Sofras F. Impact of additional sampling in the TRUS-guided biopsy for the diagnosis of prostate cancer. Urol Int. 2007;78(4):313-7.
14. Taymoorian K, Thomas A, Slowinski T, Khiabanchian M, Stephan C, Lein M, Deger S, Lenk S, Loening SA, Fischer T. Transrectal broadband-Doppler sonography with intravenous contrast medium administration for prostate imaging and biopsy in men with an elevated PSA value and previous negative biopsies. Anticancer Res. 2007 Nov-Dec;27(6C):4315-20.
15. Anand SS, Singh H, Dash AK. Clinical Applications of PET and PET-CT. Med J Armed Forces India. 2009 Oct;65(4):353-8.
16. Cuccurullo V, Di Stasio GD, Mansi L. Nuclear Medicine in Prostate Cancer: A New Era for Radiotracers. World J Nucl Med. 2018 Apr-Jun;17(2):70-78.
17. Banker, H., & Selvarajan, S. K. (2023). Prostate Imaging. In *StatPearls [Internet]*. StatPearls Publishing.

تصوير البروستات: ملاحظات لأخصائي الأشعة والممرضين والعاملين في الصحة العامة

الملخص:

الخلفية :تعتبر غدة البروستات مكونًا حيويًا في الجهاز التناسلي الذكري، وهي عرضة للإصابة بأمراض مختلفة مثل تضخم البروستات الحميد(BPH) ، والتهاب البروستات، وسرطان البروستات. تلعب تقنيات التصوير دورًا حاسمًا في تشخيص هذه الحالات وتحديد مراحلها وإدارتها، حيث توفر تقنيات مثل التصوير المقطعي المحوسب(CT) ، والتصوير بالرنين المغناطيسي(MRI) ، والتصوير بالموجات فوق الصوتية(US) ، والطب النووي مزايا فريدة. بالإضافة إلى التصوير، يلعب التمريض والصحة العامة أدوارًا محورية في تثقيف المرضى، الكشف المبكر، وإدارة الحالات المرتبطة بالبروستات.

الهدف :تهدف هذه المقالة إلى تقديم نظرة شاملة حول تقنيات التصوير المستخدمة في تقييم البروستات، مع تسليط الضوء على أدوارها في تشخيص وإدارة الحالات المرتبطة بالبروستات. بالإضافة إلى ذلك، تؤكد على مساهمات التمريض والصحة العامة في رعاية البروستات.

الطرق :تناقش المراجعة السمات التشريحية والنسيجية للبروستات، تليها تحليل مفصل لتقنيات التصوير بما في ذلكCT ، وMRI، وUS، والطب النووي. يتم استكشاف نقاط القوة والقيود لكل تقنية وتطبيقاتها المحددة في تشخيص تضخم البروستات الحميد، والتهاب البروستات، وسرطان البروستات. كما يتم مناقشة التقنيات المتقدمة مثل التصوير بالرنين المغناطيسي متعدد الوسائط(mp-MRI) ، والتصوير المرن(elastography) ، والتصوير بالموجات فوق الصوتية المعزز بالتباين .(CEUS) يتم دمج أدوار التمريض في رعاية المرضى والصحة العامة في التوعية والوقاية في المناقشة.

النتائج :يعد التصوير المقطعي المحوسب (CT) مفيدًا في تحديد مراحل سرطان البروستات وتقييم الانتشار النقيلي، لكنه يتمتع بدقة محدودة في تصوير تفاصيل تشريح البروستات. بينما يتفوق التصوير بالرنين المغناطيسي(MRI) ، خاصةًmp-MRI ، في اكتشاف الأورام الخبيثة، وتوجيه الخزعات، والتمييز بين مناطق البروستات. ويستخدم التصوير بالموجات فوق الصوتية، وخاصةً التصوير عبر المستقيم(TRUS) ، على نطاق واسع لتقييم حجم البروستات وتوجيه الخزعات، مع تحسين التقنيات المتقدمة مثل التصوير المرن و CEUSدقة التشخيص. كما يعد الطب النووي، بما في ذلك التصوير المقطعي بالإصدار البوزيتروني (PET/CT) والتصوير باستخدامPSMA ، لا يقدر بثمن في اكتشاف النقائل وتوجيه العلاج. يلعب التمريض دورًا حاسمًا في تثقيف المرضى، إدارة الأعراض، والرعاية بعد الإجراءات، بينما تركز مبادرات الصحة العامة على الكشف المبكر، برامج الفحص، والحد من التفاوتات الصحية.

الاستنتاج :يعد التصوير أمرًا لا غنى عنه في تشخيص وإدارة أمراض البروستات. يعتبر التصوير بالرنين المغناطيسي والموجات فوق الصوتية فعالين بشكل خاص في حالات الأمراض الموضعية، بينما يعد الطب النووي والتصوير المقطعي المحوسب ضروريين لتحديد المراحل وتقييم الانتشار النقيلي. تستمر التطورات في تكنولوجيا التصوير في تعزيز دقة التشخيص وتحسين النتائج العلاجية. يعتبر التمريض والصحة العامة جزءًا لا يتجزأ من الرعاية الشاملة للبروستات، مما يضمن نهجًا يركز على المريض وتدخلات على مستوى السكان لتحسين النتائج.

الكلمات المفتاحية :تصوير البروستات، التصوير بالرنين المغناطيسي، التصوير المقطعي المحوسب، التصوير بالموجات فوق الصوتية، الطب النووي، تضخم البروستات الحميد، سرطان البروستات، التهاب البروستات، التمريض، الصحة العامة.